Diakonos Oncology
Developer of a clinical-stage immunotherapy platform intended to focus on treating aggressive cancers. The company utilizes a proprietary double-loaded, patient-derived dendritic cell therapeutic tech...
Valuation
$0
Share Price
N/A
Total Raised
$31.4M
Last Round
N/A